Beckley Waves has announced the strategic acquisition of Nue Life, a leading ketamine-assisted therapy provider. Beckley Waves plans to continue Nue Life’s work to provide scalable access to ketamine-assisted therapy, with an emphasis on underserved areas.
Nue Life is a U.S.-based telemedicine startup that combines psychedelic-assisted therapies and a health-tracking app. Nue Life has provided at-home ketamine therapy to more than 10,000 patients across 23 U.S. states since 2021.
Beckley Waves, a U.K.-based venture studio co-founded by Amanda Feilding, builds and supports the companies and infrastructure needed for the delivery of new psychedelic medicines.
As part of the acquisition, Beckley Waves has launched a new portfolio company, NueCo Holdings PBC, which acquired the assets of Nue Life. Daniel Love, co-founder and partner at Beckley Waves, will act as interim Chief Executive Officer of NueCo Holdings and work alongside much of Nue Life’s existing management team. Financial terms of the deal were not disclosed.
According to data captured in the LevinPro HC database, this transaction marks the eighth infusion services acquisition of 2023. This is an approximately 70% decrease from last year when there were 26 infusion services deals announced between January 1, 2022, and October 26, 2022.
